No Data
No Data
[Brokerage Focus] Guosen Securities maintains a "outperform" rating on Weigao Group (01066), indicating that the performance growth is affected by the price adjustment of its transitional period products.
Guosen Securities released a research report that Weigao Group (01066) achieved a revenue of 6.636 billion (-3.8%) in the first half of the year. Excluding the year-on-year decline of 2.2% in epidemic-related products compared to the same period last year, it increased by 4.8% in the second quarter of 2023. The net profit attributable to the parent company was 1.108 billion (-7.5%), an increase of 37.7% compared to the previous quarter. The sales volume of products in various business sectors generally increased, with further increase in the market share of core products and continuous strengthening of brand influence. However, product prices are still in the process of transitioning from old to new policies, which has a certain impact on the growth rate of performance. The board of directors recommends a mid-term dividend of approximately 0.42 billion.
We Think Shandong Weigao Group Medical Polymer (HKG:1066) Can Stay On Top Of Its Debt
Shandong Weigao Group Sets Key EGM on Dividend and Board Powers
Express News | Shandong Weigao Group Medical Polymer H1 EPS RMB 0.24
WEIGAO GROUP: INTERIM REPORT 2024
Hong Kong stocks fluctuated | Medical device stocks rose in early trading, with micro-invasive stocks leading the gains. The National Medical Products Administration said it would spare no effort in promoting the research and development innovation of med
Medical device stocks collectively rose. As of the time of publication, Siasun Robot&Automation-B (02252) rose by 11.46% to HK$7.22; Microport (00853) rose by 8.48% to HK$4.99; AK Medical (01789) rose by 5.73% to HK$4.06; Microport Neurotech (02172) rose by 2.38% to HK$7.75; Weigao Group (01066) rose by 2.09% to HK$4.40.
No Data
No Data